Company Takes Charge in Effort to Convert Embryonic Stem Cells to Islets


By: Daniel Trecroci

Novocell, Inc., a San Diego, California-based stem cell engineering company, announced on October 19, 2006, the development of a process that “efficiently converts human embryonic stem cells into insulin-producing pancreatic endocrine cells.”

“Such an approach could provide a means to produce sufficient quantities of insulin-producing cells for transplantation into patients with type 1 diabetes,” writes Novocell in a press release, “a treatment that offers a potential therapy for this disease.”

* * *

Source: Novocell, Inc.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.